The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Currently enrolling trials
An Open-Label Pilot Study of Apremilast in Chronic Idiopathic Pruritus
Principal investigator: Brian Kim, MD
A Phase 3 Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 and Fluoroscent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma.
Principal investigator: Amy Musiek, MD
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL). Protocol EL-1007-01-01
Principal investigator: Amy Musiek, MD
PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Principal investigator: Lynn Cornelius, MD
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations. Protocol 230LE201
Principal investigator: Milan Anadkat, MD
A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by A Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
Principal investigator: Ann Martin, MD
Upcoming trials
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis
Principal investigator: Ann Martin, MD
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis.
Principal investigator: Ann Martin, MD
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis
Principal investigator: Ann Martin, MD
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients with Moderate to Severe Acne Vulgaris
Principal investigator: Ann Martin, MD
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects with Moderate to Severe Hidradenitis Suppurativa
Prinicpal investigator: Milan Anadkat, MD
Contact
Mary Tabacchi, Clinical Research Coordinator
314-362-8171
mtabacchi@wustl.edu